Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan

Press ReleaseNicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan Exclusive Japanese partner Kowa has received regulatory approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in JapanMilestone payments from Kowa totaling €3 million expected to be received by Nicox in 2025Extends Nicox's cash runway until the end of 2025May 27, 2025 – release...

Biot, 27/05/2025 (informazione.news - comunicati stampa - salute e benessere)

Attachment